CARL G. CHAKMAKJIAN
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
- Where
- Gatesville, TX
- NPI
- 1285675306
- Received
- $272,592 in 294 records, 2019 to 2025
- As principal investigator
- $587,931 of research payments to others in 129 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 46 | $56,773 |
| 2024 | General payment | 48 | $24,850 |
| 2023 | General payment | 37 | $17,950 |
| 2022 | General payment | 51 | $40,858 |
| 2021 | General payment | 31 | $40,600 |
| 2020 | General payment | 19 | $16,737 |
| 2019 | General payment | 62 | $74,822 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 51 | $219,537 |
| Consulting Fee | 30 | $24,624 |
| Travel and Lodging | 57 | $23,207 |
| Food and Beverage | 151 | $5,074 |
| Education | 5 | $150 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-24 | TerSera Therapeutics LLC | $32 | Food and Beverage | In-kind items and services | Zoladex Drug, Oncology | 2025 | |
| 2025-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $29 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-26 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-10 | Kite Pharma, Inc. | $32 | Food and Beverage | In-kind items and services | Yescarta Drug, CELLT | 2025 | |
| 2025-11-04 | BIOPROTECT MEDICAL, INC. | $13 | Food and Beverage | In-kind items and services | BIOPROTECT BALLOON IMPLANT SYSTEM Device, Rectal Spacers Used in Prostate Cancer Radiation Therapy | 2025 | |
| 2025-10-28 | E.R. Squibb & Sons, L.L.C. | $162 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-22 | Merck Sharp & Dohme LLC | $21 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-10-21 | E.R. Squibb & Sons, L.L.C. | $9,315 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-10-15 | SOBI, INC | $17 | Food and Beverage | In-kind items and services | Vonjo Drug, Hematology/Oncology | 2025 | |
| 2025-10-01 | E.R. Squibb & Sons, L.L.C. | $222 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-09-17 | E.R. Squibb & Sons, L.L.C. | $518 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-09-17 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-10 | E.R. Squibb & Sons, L.L.C. | $5,693 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-08-20 | PFIZER INC. | $26 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-08-06 | Astellas Pharma US Inc | $18 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2025 | |
| 2025-07-24 | E.R. Squibb & Sons, L.L.C. | $518 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-24 | Novartis Pharmaceuticals Corporation | $25 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-07-16 | TAIHO ONCOLOGY, INC. | $20 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2025 | |
| 2025-07-15 | E.R. Squibb & Sons, L.L.C. | $518 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | Janssen Biotech, Inc. | $39 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-05-21 | Lilly USA, LLC | $26 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2025 | |
| 2025-05-20 | Aveo Pharmaceuticals, Inc. | $20 | Education | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-05-18 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-05-15 | E.R. Squibb & Sons, L.L.C. | $2,070 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-15 | E.R. Squibb & Sons, L.L.C. | $2,070 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-05-14 | E.R. Squibb & Sons, L.L.C. | $57 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-05-12 | E.R. Squibb & Sons, L.L.C. | $7,245 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-05-07 | AstraZeneca Pharmaceuticals LP | $30 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2025 | |
| 2025-04-25 | E.R. Squibb & Sons, L.L.C. | $9,315 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-04-17 | E.R. Squibb & Sons, L.L.C. | $89 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-04-16 | Astellas Pharma US Inc | $32 | Food and Beverage | In-kind items and services | Vyloy Drug, Oncology | 2025 | |
| 2025-04-11 | E.R. Squibb & Sons, L.L.C. | $3 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-04-07 | E.R. Squibb & Sons, L.L.C. | $11,385 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-04-03 | E.R. Squibb & Sons, L.L.C. | $206 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-04-03 | E.R. Squibb & Sons, L.L.C. | $55 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-27 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-03-19 | PFIZER INC. | $20 | Food and Beverage | In-kind items and services | BOSULIF Drug, METABOLIC DISEASE;ONCOLOGY | 2025 | |
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $1,250 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $895 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $329 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-03-18 | E.R. Squibb & Sons, L.L.C. | $125 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | $2,070 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-25 | E.R. Squibb & Sons, L.L.C. | $2,070 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-02-19 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-02-05 | GlaxoSmithKline, LLC. | $23 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-01-15 | Merck Sharp & Dohme LLC | $34 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2024-12-20 | E.R. Squibb & Sons, L.L.C. | $5,082 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-12-18 | E.R. Squibb & Sons, L.L.C. | $67 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-12-18 | AstraZeneca Pharmaceuticals LP | $23 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-12-11 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-11-21 | E.R. Squibb & Sons, L.L.C. | $1,101 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-21 | E.R. Squibb & Sons, L.L.C. | $1,051 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-21 | E.R. Squibb & Sons, L.L.C. | $169 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-21 | E.R. Squibb & Sons, L.L.C. | $123 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-11-20 | GlaxoSmithKline, LLC. | $19 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2024 | |
| 2024-11-12 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2024 | |
| 2024-11-06 | Genmab U.S., Inc. | $21 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2024 | |
| 2024-11-05 | Celgene Corporation | $15 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2024-10-24 | SOBI, INC | $16 | Food and Beverage | In-kind items and services | VONJO Drug, HEMATOLOGY/ONCOLOGY | 2024 | |
| 2024-10-17 | Tempus AI, Inc | $15 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-10-16 | Regeneron Healthcare Solutions, Inc. | $26 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-10-10 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-10-02 | Celgene Corporation | $20 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2024-09-18 | ADC THERAPEUTICS AMERICA, INC. | $14 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-09-04 | E.R. Squibb & Sons, L.L.C. | $576 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-08-21 | Eisai Inc. | $33 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-08-13 | ADC THERAPEUTICS AMERICA, INC. | $13 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-07-22 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2024 | ||
| 2024-07-17 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | CALQUENCE Drug, Oncology | 2024 | |
| 2024-06-20 | PFIZER INC. | $11 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2024 | |
| 2024-05-23 | Regeneron Healthcare Solutions, Inc. | $23 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2024 | |
| 2024-05-23 | GENZYME CORPORATION | $13 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2024 | |
| 2024-05-14 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-05-08 | Eisai Inc. | $25 | Food and Beverage | In-kind items and services | Lenvima Drug, Oncology | 2024 | |
| 2024-05-06 | E.R. Squibb & Sons, L.L.C. | $5,717 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AUGTYRO Drug, Oncology | 2024 | |
| 2024-05-01 | Gilead Sciences, Inc. | $20 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-04-29 | E.R. Squibb & Sons, L.L.C. | $4,447 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-26 | E.R. Squibb & Sons, L.L.C. | $238 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-25 | E.R. Squibb & Sons, L.L.C. | $82 | Food and Beverage | Cash or cash equivalent | AUGTYRO Drug, Oncology | 2024 | |
| 2024-04-18 | E.R. Squibb & Sons, L.L.C. | $23 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-17 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-04-10 | E.R. Squibb & Sons, L.L.C. | $4,447 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-10 | Bayer Healthcare Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2024 | |
| 2024-04-08 | Merck Sharp & Dohme LLC | $27 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2024 | |
| 2024-04-05 | E.R. Squibb & Sons, L.L.C. | $159 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2024 | |
| 2024-04-03 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | Fabhalta Drug, Immunology | 2024 | |
| 2024-03-20 | Incyte Corporation | $22 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2024 | |
| 2024-03-07 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2024-03-01 | Novartis Pharmaceuticals Corporation | $17 | Food and Beverage | In-kind items and services | MEKINIST Drug, Oncology | 2024 | |
| 2024-02-20 | PUMA BIOTECHNOLOGY, INC. | $17 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-02-07 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2024 | |
| 2024-01-24 | Novartis Pharmaceuticals Corporation | $23 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2024 | |
| 2024-01-17 | Takeda Pharmaceuticals U.S.A., Inc. | $24 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2024 | |
| 2024-01-04 | Celgene Corporation | $17 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2024 | |
| 2023-12-29 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-20 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-12-13 | GlaxoSmithKline, LLC. | $18 | Food and Beverage | In-kind items and services | OJJAARA Drug, ONCOLOGY | 2023 | |
| 2023-12-06 | EMD Serono, Inc. | $19 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-11-15 | TAIHO ONCOLOGY, INC. | $20 | Food and Beverage | In-kind items and services | LONSURF Drug, Oncology | 2023 | |
| 2023-11-14 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-11-08 | Daiichi Sankyo Inc. | $21 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2023 | |
| 2023-11-01 | Janssen Biotech, Inc. | $36 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2023 | |
| 2023-10-27 | E.R. Squibb & Sons, L.L.C. | $4,658 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-10-23 | BeiGene USA, Inc. | $15 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2023 | |
| 2023-10-12 | Lilly USA, LLC | $18 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2023 | |
| 2023-10-05 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | MONJUVI Drug, Oncology | 2023 | |
| 2023-09-27 | MENARINI SILICON BIOSYSTEMS, INC. | $14 | Food and Beverage | In-kind items and services | Cellsearch Device, Diagnostics | 2023 | |
| 2023-09-20 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-09-20 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-08-03 | Mirati Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | KRAZATI Drug, ONCOLOGY | 2023 | |
| 2023-07-20 | Eisai Inc. | $18 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-07-05 | PharmaEssentia USA Corporation | $32 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2023 | |
| 2023-06-21 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-06-07 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-05-26 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | RETEVMO Drug, Oncology | 2023 | |
| 2023-05-24 | GENZYME CORPORATION | $29 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2023 | |
| 2023-05-17 | Stemline Therapeutics Inc. | $18 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2023 | |
| 2023-05-16 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2023 | |
| 2023-05-03 | Amgen Inc. | $18 | Food and Beverage | In-kind items and services | LUMAKRAS Drug, Oncology | 2023 | |
| 2023-05-02 | E.R. Squibb & Sons, L.L.C. | $4,658 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-04-20 | Bayer Healthcare Pharmaceuticals Inc. | $28 | Food and Beverage | In-kind items and services | Stivarga Drug, Oncology | 2023 | |
| 2023-04-18 | Sirtex Medical Inc | $22 | Food and Beverage | Cash or cash equivalent | SIR-Spheres Microspheres Device, Interventional Oncology | 2023 | |
| 2023-04-05 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | PIQRAY Drug, Oncology | 2023 | |
| 2023-03-01 | Mirati Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | KRAZATI Drug, ONCOLOGY | 2023 | |
| 2023-02-15 | PUMA BIOTECHNOLOGY, INC. | $21 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-02-08 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-31 | E.R. Squibb & Sons, L.L.C. | $195 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-01-31 | E.R. Squibb & Sons, L.L.C. | $75 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-01-31 | E.R. Squibb & Sons, L.L.C. | $37 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-01-17 | E.R. Squibb & Sons, L.L.C. | $4,310 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-01-03 | E.R. Squibb & Sons, L.L.C. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2022-12-21 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-12-09 | E.R. Squibb & Sons, L.L.C. | $336 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-12-07 | Adaptive Biotechnologies Corporation | $19 | Food and Beverage | In-kind items and services | clonoSEQ Device, B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | 2022 | |
| 2022-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | $21 | Food and Beverage | In-kind items and services | NINLARO Drug, ONCOLOGY | 2022 | |
| 2022-11-16 | E.R. Squibb & Sons, L.L.C. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-09 | E.R. Squibb & Sons, L.L.C. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-08 | Boston Scientific Corporation | $13 | Food and Beverage | In-kind items and services | SpaceOAR VUE System - 10mL Device, SpaceOAR VUE_URO | 2022 | |
| 2022-11-03 | E.R. Squibb & Sons, L.L.C. | $109 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-11-02 | SEAGEN INC. | $16 | Food and Beverage | In-kind items and services | ADCETRIS Biological, Oncology | 2022 | |
| 2022-10-20 | Novartis Pharmaceuticals Corporation | $21 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-10-19 | Janssen Biotech, Inc. | $28 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2022 | |
| 2022-10-17 | Merck Sharp & Dohme LLC | $24 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-10-12 | E.R. Squibb & Sons, L.L.C. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-10-12 | E.R. Squibb & Sons, L.L.C. | $172 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-10-06 | Ipsen Biopharmaceuticals, Inc | $19 | Food and Beverage | In-kind items and services | SOMATULINE DEPOT Drug, Oncology/Endocrinology | 2022 | |
| 2022-09-28 | Regeneron Healthcare Solutions, Inc. | $31 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2022 | |
| 2022-09-22 | E.R. Squibb & Sons, L.L.C. | $85 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-09-21 | Merck Sharp & Dohme LLC | $18 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-09-14 | Karyopharm Therapeutics Inc. | $25 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2022 | |
| 2022-09-06 | Incyte Corporation | $14 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2022 | |
| 2022-09-01 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | CABLIVI Biological, Hematology | 2022 | |
| 2022-08-09 | PharmaEssentia USA Corporation | $15 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2022 | |
| 2022-08-03 | Celgene Corporation | $0 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2022 | |
| 2022-08-02 | E.R. Squibb & Sons, L.L.C. | $5,625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-07-21 | Lilly USA, LLC | $16 | Food and Beverage | In-kind items and services | VERZENIO Drug, Oncology | 2022 | |
| 2022-07-14 | E.R. Squibb & Sons, L.L.C. | $98 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-07-12 | E.R. Squibb & Sons, L.L.C. | $210 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-29 | Bayer Healthcare Pharmaceuticals Inc. | $15 | Food and Beverage | In-kind items and services | Xofigo Drug, Oncology | 2022 | |
| 2022-06-21 | E.R. Squibb & Sons, L.L.C. | $4,310 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-15 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-06-15 | Myriad Genetic Laboratories, Inc. | $12 | Food and Beverage | Cash or cash equivalent | myRisk Device, Germline DNA Sequencing Hereditary Cancer and Rearrangement Analysis | 2022 | |
| 2022-06-13 | E.R. Squibb & Sons, L.L.C. | $409 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-13 | E.R. Squibb & Sons, L.L.C. | $5 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-09 | E.R. Squibb & Sons, L.L.C. | $84 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-06-07 | E.R. Squibb & Sons, L.L.C. | $4,310 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-26 | SEAGEN INC. | $15 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2022 | |
| 2022-05-19 | E.R. Squibb & Sons, L.L.C. | $125 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-19 | E.R. Squibb & Sons, L.L.C. | $100 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-18 | E.R. Squibb & Sons, L.L.C. | $8 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-17 | E.R. Squibb & Sons, L.L.C. | $2,635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-10 | E.R. Squibb & Sons, L.L.C. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-05-05 | Janssen Biotech, Inc. | $15 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2022 | |
| 2022-04-28 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-04-19 | E.R. Squibb & Sons, L.L.C. | $2,635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-03-31 | E.R. Squibb & Sons, L.L.C. | $355 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-03-21 | Celgene Corporation | $600 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-02-16 | E.R. Squibb & Sons, L.L.C. | $300 | Consulting Fee | Cash or cash equivalent | 2022 | ||
| 2022-01-04 | E.R. Squibb & Sons, L.L.C. | $2,635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-01-04 | E.R. Squibb & Sons, L.L.C. | $136 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-01-04 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-01-04 | E.R. Squibb & Sons, L.L.C. | $10 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2021-12-20 | E.R. Squibb & Sons, L.L.C. | $5,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-12-14 | E.R. Squibb & Sons, L.L.C. | $1,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-12-14 | E.R. Squibb & Sons, L.L.C. | $224 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-11-26 | E.R. Squibb & Sons, L.L.C. | $600 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-11-18 | E.R. Squibb & Sons, L.L.C. | $1,192 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-11-18 | E.R. Squibb & Sons, L.L.C. | $425 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-11-18 | E.R. Squibb & Sons, L.L.C. | $133 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-11-18 | E.R. Squibb & Sons, L.L.C. | $122 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-10-12 | E.R. Squibb & Sons, L.L.C. | $2,635 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-21 | E.R. Squibb & Sons, L.L.C. | $5,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-21 | E.R. Squibb & Sons, L.L.C. | $136 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-21 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-21 | E.R. Squibb & Sons, L.L.C. | $20 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-02 | E.R. Squibb & Sons, L.L.C. | $203 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-09-02 | E.R. Squibb & Sons, L.L.C. | $77 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-08-24 | E.R. Squibb & Sons, L.L.C. | $5,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-08-24 | E.R. Squibb & Sons, L.L.C. | $145 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2021 | |
| 2021-08-19 | Janssen Biotech, Inc. | $122 | Food and Beverage | In-kind items and services | DARZALEX Biological, Oncology | 2021 |
The latest 200 records of 294.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | Merck Sharp & Dohme LLC | Texas Oncology - Central,South Texas | $564 | KEYMAKER-U01 Substudy 01E# A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemothe | 2025 |
| 2025-11-27 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $2,945 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-10-29 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-08-22 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-07-29 | AstraZeneca Pharmaceuticals LP | TEXAS ONCOLOGY BAYLOR CHARLES A SAMMONS CANCER CENTER | $16,750 | A Phase III, Open-label, Randomized Study of Osimertinib with or without Datopotamab deruxtecan (Dato-DXd), as First-lin | 2025 |
| 2025-05-26 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-05-26 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-02-07 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2025 |
| 2025-01-15 | Eli Lilly and Company | Texas Oncology PA | $3,187 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2025 |
| 2024-11-25 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $1,125 | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLYADVANCED | 2024 |
| 2024-10-28 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 |
| 2024-10-15 | PFIZER INC. | Texas Oncology PA | $956 | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED | 2024 |
| 2024-05-27 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 |
| 2024-04-15 | PFIZER INC. | Texas Oncology Waco | $956 | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED | 2024 |
| 2024-02-08 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 |
| 2024-01-19 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,528 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 |
| 2024-01-19 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $2,587 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2024 |
| 2024-01-15 | PFIZER INC. | Texas Oncology Waco | $956 | A PHASE 2 BASKET STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB IN SUBJECTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED | 2024 |
| 2024-01-15 | Eli Lilly and Company | Texas Oncology PA | $4,250 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2024 |
| 2024-01-02 | Eli Lilly and Company | US ONCOLOGY RESEARCH LLC | $1,422 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2024 |
| 2023-10-18 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-10-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2023 |
| 2023-07-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2023 |
| 2023-07-06 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $2,060 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-07-03 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-06-06 | E.R. Squibb & Sons, L.L.C. | US ONCOLOGY RESEARCH LLC | $36,402 | A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cance | 2023 |
| 2023-05-23 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-04-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2023 |
| 2023-04-12 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $588 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-04-12 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $47 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-02-27 | Eli Lilly and Company | US ONCOLOGY RESEARCH LLC | $5,688 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2023 |
| 2023-02-07 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $176 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-31 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $38 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-26 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-24 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $2,945 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-24 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $2,587 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-24 | GlaxoSmithKline, LLC. | US Oncology ResearchLLC | $1,528 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2023 |
| 2023-01-15 | AstraZeneca Pharmaceuticals LP | TEXAS ONCOLOGY SOUTHWEST FORT WORTH | $3,934 | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small C | 2023 |
| 2023-01-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2023 |
| 2023-01-15 | Eli Lilly and Company | Texas Oncology PA | $10,300 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2023 |
| 2022-12-06 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-10-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-09-05 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-09-05 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-09-05 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-08-28 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $2,671 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-08-17 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $1,125 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-08-17 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $9,500 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-07-15 | SEAGEN INC. | Texas Oncology - Waco | $2,000 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-07-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-07-14 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $5,194 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-06-17 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $3,894 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-06-03 | GlaxoSmithKline, LLC. | US ONCOLOGY RESEARCH INC | $4,097 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S | 2022 |
| 2022-04-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-03-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-03-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-03-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-03-01 | Eli Lilly and Company | US ONCOLOGY RESEARCH LLC | $8,704 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2022 |
| 2022-02-15 | SEAGEN INC. | Texas Oncology - Waco | $150 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-02-15 | SEAGEN INC. | Texas Oncology - Waco | $1,200 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-02-15 | SEAGEN INC. | Texas Oncology - Waco | $150 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-02-08 | Novartis Pharmaceuticals Corporation | TEXAS ONCOLOGY | $5 | A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH A | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-15 | Eli Lilly and Company | Texas Oncology PA | $10,601 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $956 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $1,111 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $1,200 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $776 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2022 |
| 2022-01-07 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $7,343 | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) | 2022 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $816 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $1,111 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-12-15 | SEAGEN INC. | Texas Oncology - Waco | $1,600 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $1,111 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $1,837 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-11-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-27 | SEAGEN INC. | Texas Oncology - Waco | $2,700 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-27 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - Waco | $1,200 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - Waco | $3,251 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-10-15 | SEAGEN INC. | Texas Oncology - Waco | $250 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-09-15 | SEAGEN INC. | Texas Oncology - Waco | $6,800 | A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advance | 2021 |
| 2021-06-18 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $2,250 | A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cance | 2021 |
| 2021-04-15 | Janssen Research & Development, LLC | Tx Oncology Corprt Ofc | $926 | Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrati | 2021 |
| 2021-04-15 | Janssen Research & Development, LLC | Tx Oncology Corprt Ofc | $458 | Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrati | 2021 |
| 2021-02-12 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $2,694 | An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) | 2021 |
| 2021-01-26 | Eli Lilly and Company | US ONCOLOGY RESEARCH LLC | $38,283 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2021 |
| 2021-01-15 | E.R. Squibb & Sons, L.L.C. | TEXAS ONCOLOGY | $1,912 | Phase IIIb IV Safety Trial of Nivolumab BMS-936558 in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer | 2021 |
| 2021-01-15 | Eli Lilly and Company | Texas Oncology PA | $37,800 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2021 |
| 2021-01-05 | Eli Lilly and Company | Texas Oncology PA | $0 | A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN | 2021 |
| 2020-10-15 | Janssen Research & Development, LLC | Tx Oncology, Pa | $458 | Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrati | 2020 |
| 2020-10-15 | Janssen Research & Development, LLC | Tx Oncology, Pa | $926 | Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrati | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Gatesville, TX, county Coryell County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Gatesville, TX | County Coryell County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 16,228 | 84,748 | 30,188,424 |
| Population, 2020 census P1 | 16,135 | 83,093 | 29,145,505 |
| Median age B01002 | 39.4 | 32.8 | 35.6 |
| Under 18 B01001 | 8.6% | 22.5% | 25.0% |
| 65 and over B01001 | 11.1% | 11.4% | 13.4% |
| Households B11001 | 3,082 | 26,986 | 10,992,816 |
| Foreign born B05002 | 6.2% | 6.1% | 17.6% |
| Median household income B19013 | $57,217 | $71,301 | $78,476 |
| Median family income B19113 | $70,870 | $80,659 | $94,599 |
| Per capita income B19301 | $17,236 | $30,066 | $40,752 |
| Poverty rate B17001 | 9.1% | 11.2% | 13.8% |
| Unemployment rate B23025 | 4.5% | 7.1% | 5.3% |
| Civilian labor force B23025 | 3,066 | 27,003 | 15,233,563 |
| Mean commute (minutes) B08013 | 22.8 | 24.4 | 26.7 |
| Bachelor's degree or higher B15003 | 8.6% | 19.3% | 33.8% |
| Housing units B25001 | 3,288 | 29,512 | 12,128,515 |
| Owner-occupied B25003 | 63.9% | 58.6% | 62.6% |
| Renters B25003 | 36.1% | 41.4% | 37.4% |
| Median home value B25077 | $207,300 | $195,300 | $283,800 |
| Median gross rent B25064 | $1,007 | $1,186 | $1,403 |
| White, not Hispanic B03002 | 49.9% | 54.4% | 39.1% |
| Black B03002 | 15.6% | 13.0% | 11.9% |
| Hispanic or Latino B03002 | 26.4% | 20.7% | 39.7% |
| Asian B03002 | 1.3% | 2.0% | 5.5% |
| American Indian and Alaska Native B03002 | 0.6% | 0.3% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Gatesville, TX.
Comments